Abstract: FR-PO040
The Influence of Left Ventricular Assist Device Implantation on Short-Term and Long-Term Renal Functions in End-Stage Heart Failure Patients
Session Information
- AKI: Clinical Outcomes, Trials
November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical, Outcomes, and Trials
Authors
- Sadigov, Anar, Ege University Medical Faculty, Izmir, Turkey
- Demir, Emre, Ege University Medical Faculty, Izmir, Turkey
- Nalbantgil, Sanem, Ege University Medical Faculty, Izmir, Turkey
- Demirci, Cenk, Fresenius Medical Care, Izmir, Turkey
- Engin, Cagatay, Ege University Medical Faculty, Izmir, Turkey
- Yagdi, Tahir, Ege University Medical Faculty, Izmir, Turkey
- Ozturk, Pelin, Ege University Medical Faculty, Izmir, Turkey
- Ozbaran, Mustafa, Ege University Medical Faculty, Izmir, Turkey
- Sezis Demirci, Meltem, Ege University Medical Faculty, Izmir, Turkey
Group or Team Name
- Ege University
Background
Left Ventricular Assist Devices(LVAD) are used as an interventional treatment method for patients with decompensated heart failure(HF).The aim of this study is to retrospectively evaluate the short and long-term effects of LVAD implantation on renal function and survival in patients with end-stage HF.
Methods
329 patients with LVAD were investigated. Basal and follow-up GFR(CKD-Epi) values were calculated retrospectively. Patients were divided into three groups according to baseline GFR; group 1(GFR<60,n=85), group 2(GFR 60-90,n=138) and group 3(GFR>90,n=106). SPSS 22.0 software was used for all statistical analyses.
Results
The mean age of the patients was 50.8±13.2, 86% was male, mean basal GFR was 77.6±25.7 ml/min, 29.5% patients had DM, 34.1% had HT. Mean follow-up time was 22.6±17.9(0,2-71,6) months.There was a significant increase in mean GFR values of all patients in the postop first month(p <0.01). In group 1, there was a significant increase in GFR at 1, 12, 24 months after implantation compared to baseline(p<0.001), but this increase was not significant at 36 months(p=0.08). One-year transplantation-censored survival was 81.9%, 70.3% for 2-year, 55.8% for 4 and 5-years. The survival rate at first year was 87.9% in group 3, 81.9% in group 2 and 76.2% in group 1. Patients with postoperation first month GFR increased(n=227); 2-year survival rate was 73%, 4-year was 58% and patients with not increased group(n=69), 2-year survival rate was 56% and 4-year was 38%(p <0.01).
Conclusion
In patients with LVAD, short- and long-term results are quite good in terms of renal function. Even though GFR was low before, we observed that there was a significant improvement in GFR after LVAD implantation and this improvement continued for the first 3 years.